Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2015 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma
2013
Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection
2011
Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria
2009
Source control in the management of severe sepsis and septic shock: An evidence-based review
2004
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Public health policies and alcohol-related liver disease
2019
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Cancer Statistics, 2021
2021 Standout
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Global epidemiology and genotype distribution of the hepatitis C virus infection
2014
Auditory and non-auditory effects of noise on health
2013 Standout
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus
2009
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Hepatocellular carcinoma
2018 Standout
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review
2010
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
2009
Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C
2013
Interaction between cigarette, alcohol and betel nut use on esophageal cancer risk in Taiwan
2006
Burden of liver diseases in the world
2018 Standout
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 Standout
Molecular diagnosis of viral hepatitis
2002
The Prevalence of Metabolic Syndrome In Non-alcoholic Fatty Liver Disease; A Population-Based Study
2016
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
2008
Steatosis and insulin resistance in response to treatment of chronic hepatitis C
2012
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
2008
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
2020
Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments
2014
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
2017
A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
2011
Retinopathy of prematurity
2013 Standout
Hepatocellular carcinoma
2012 Standout
Hepatitis B virus infection
2009 Standout
Hepatocellular carcinoma
2021 Standout
Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan
2021
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma
2016
Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient
2005
Transfusion Medicine — Blood Transfusion
1999 Standout
Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes
2007
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Chronic kidney disease
2011 Standout
Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis
2018
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Global cancer statistics
2011 Standout
Two to Tango: Regulation of Mammalian Iron Metabolism
2010 Standout
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
2017
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
2005
Rapid Regulation of Depression-Associated Genes in a New Mouse Model Mimicking Interferon-α-Related Depression in Hepatitis C Virus Infection
2014
Animal models in the study of hepatitis C virus-associated liver pathologies
2011
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Non-alcoholic fatty liver disease
2021 Standout
Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
2008
Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa
2009
Sepsis and septic shock
2018 Standout
Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk
2015
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
2007
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
2010
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
2015 StandoutNobel
Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease
2008
Chronic hepatitis B: Update 2009 #
2009 Standout
Expert opinion on the treatment of patients with chronic hepatitis C
2008
Global burden of liver disease: 2023 update
2023 Standout
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study
2020 Standout
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Progress towards elimination goals for viral hepatitis
2020
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection
2008
NAFLD in Asia—as common and important as in the West
2013
Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients
2008 Standout
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
2016
Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology
2015
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
2007
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
2006 Standout
Hepatocellular Carcinoma
2011 Standout
Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants
2017
Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis
2009
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma
2015
Mediators involved in retinopathy of prematurity and emerging therapeutic targets
2011
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis
2016
Update in the management of chronic hepatitis B
2013
Emerging treatments for noise-induced hearing loss
2011
Hepatocellular carcinoma
2022 Standout
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis
2017
Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference #
2009
Replication of hepatitis C virus
2007 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
RTP4 inhibits IFN-I response and enhances experimental cerebral malaria and neuropathology
2020 StandoutNobel
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
2020
AASLD guidelines for treatment of chronic hepatitis B
2015
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection
2008
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Beclin-1-Dependent Autophagy Protects the Heart During Sepsis
2018
Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study
2010
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection
2013
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Non‐alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups
2013
Screening for Hepatitis C Virus Infection in Adolescents and Adults
2020
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
2020
Beneficial Effects of Leukocyte Depletion of Transfused Blood on Postoperative Complications in Patients Undergoing Cardiac Surgery
1998
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
2010
Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796
2008
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
2015
Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
2011
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
2010 Standout
Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis
2017
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Works of Ming‐Lung Yu being referenced
Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based Study
2010
High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
2005
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
2015
A randomized trial of 24‐ vs. 48‐week courses of PEG interferon α‐2b plus ribavirin for genotype‐1b‐infected chronic hepatitis C patients: a pilot study in Taiwan
2005
APASL consensus statements and management algorithms for hepatitis C virus infection
2012
Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication
2014
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients
2009
Long-Term Effects of Interferon-Based Therapy for Chronic Hepatitis C
2007
Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C‐coinfected patients
2006
Role of insulin-like growth factor-1 (IGF-1) in regulating cell cycle progression
2009
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
2006
Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients
2015
Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study
2008
Habitual Betel Quid Chewing as a Risk Factor for Cirrhosis
2003
Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol
2016
Prevalence and manifestations of hepatitis C seropositivity in children in an endemic area
1998
Association of Polymorphisms of Heat Shock Protein 70 with Susceptibility to Noise-Induced Hearing Loss in the Taiwanese Population
2010
Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis
2019
Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy
2016
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial
2008
The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population
2011
Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?
2006
Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses
2008
Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C
2015
GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon-α therapy
2001
Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement
2020
Improvement of Nonalcoholic Fatty Liver Disease After Bariatric Surgery in Morbidly Obese Chinese Patients
2011
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
2006
Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin
2015
Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals
2019
Significant correlations between severe fatty liver and risk factors for metabolic syndrome
2006
Complete Activation of Autophagic Process Attenuates Liver Injury and Improves Survival in Septic Mice
2013
Habitual Betel Quid Chewing and Risk for Hepatocellular Carcinoma Complicating Cirrhosis
2004
Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis
2012
A 24‐week course of high‐dose interferon‐α plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near‐normal alanine aminotransferase levels
2006
Novel quasi-subgenotype D2 of hepatitis B virus identified in Taiwanese aborigines
2014
Effect of manganese-superoxide dismutase genetic polymorphisms IVS3-23T/G on noise susceptibility in Taiwan
2009
Comparison of a 6‐month course peginterferon α‐2b plus ribavirin and interferon α‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan
2005
Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals
2017
A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan
2006
Changes in lymphocyte subpopulations as a result of cardiopulmonary bypass
1991
Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon-α plus Ribavirin Combination Therapy
2006
Long‐term efficacy of Peg‐Interferon/Ribavirin with and without Lamivudine therapy for HBeAg‐positive hepatitis B and C dual infection
2015
Diagnostic Value of Immunoglobulin G (IgG) and IgM Anti-Hepatitis E Virus (HEV) Tests Based on HEV RNA in an Area Where Hepatitis E Is Not Endemic
2000
The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients
2015
Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-α-2A Therapy
2011
Early diagnosis of necrotizing fasciitis by utilization of ultrasonography.
1996
Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy
2005
Hyperlipidemia in noise‐induced hearing loss
2007
Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan
2001
Clinical Evaluation of the Automated COBAS AMPLICOR HCV MONITOR Test Version 2.0 for Quantifying Serum Hepatitis C Virus RNA and Comparison to the Quantiplex HCV Version 2.0 Test
2000
Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program
2015
Mitoferrin1 Transgenic Zebrafish Line Serves as a Model to Study Erythroid Cell Fate during Hematopoiesis
2008